ADT stock icon

ADT
ADT

$7.28
1.46%

Market Cap: $6.63B

 

About: ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. It offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. The company segments include Consumer and Small Business (CSB), Commercial, and Solar. It generates maximum revenue from the Commercial segment.

Employees: 14,300

0
Funds holding %
of 6,710 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

120% more call options, than puts

Call options by funds: $4.74M | Put options by funds: $2.15M

82% more repeat investments, than reductions

Existing positions increased: 113 | Existing positions reduced: 62

19% more capital invested

Capital invested by funds: $5.23B [Q1] → $6.22B (+$989M) [Q2]

4.34% more ownership

Funds ownership: 91.25% [Q1] → 95.59% (+4.34%) [Q2]

9% less first-time investments, than exits

New positions opened: 50 | Existing positions closed: 55

2% less funds holding

Funds holding: 264 [Q1] → 259 (-5) [Q2]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q1] → 4 (-1) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$8
10%
upside
Avg. target
$8
10%
upside
High target
$8
10%
upside

1 analyst rating

positive
0%
neutral
100%
negative
0%
RBC Capital
Ashish Sabadra
80% 1-year accuracy
35 / 44 met price target
10%upside
$8
Sector Perform
Maintained
2 Aug 2024

Financial journalist opinion

Based on 3 articles about ADT published over the past 30 days

Neutral
GlobeNewsWire
2 days ago
Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer
ORION CORPORATION PRESS RELEASE 16 SEPTEMBER 2024 at 11.30 EEST          Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer Results from the pivotal Phase III ARANOTE trial evaluating darolutamide plus androgen deprivation therapy (ADT) showed a statistically significant increase in radiological progression-free survival (rPFS) compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer Darolutamide plus ADT now has positive data both with and without docetaxel based on two pivotal Phase III studies in metastatic hormone-sensitive prostate cancer Safety analysis reconfirms the established tolerability profile of darolutamide as observed in the ARAMIS and ARASENS trials Data from ARANOTE trial presented as a late-breaking oral presentation at the ESMO 2024 Congress and simultaneously published in The Journal of Clinical Oncology Abstract: LBA68 Results from the Phase III ARANOTE trial have shown that darolutamide plus androgen deprivation therapy (ADT) significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P
Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer